Physician profile
Lisa F Donegan
NPI 1669892691
$7,620.51
in general payments reported to CMS, 2019-2025
42 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what 93% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $1,731 · 2023: $1,986 · 2024: $1,782 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,484.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $764.96 | 2023-2024 | Ultomiris, Soliris |
| Abbvie INC. | $619.87 | 2022-2024 | |
| Novo Nordisk INC | $558.01 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $521.32 | 2021-2025 | Fasenra |
| Coloplast Corp | $328.50 | 2023-2025 | Titan |
| Teva Pharmaceuticals USA, INC. | $323.53 | 2022-2025 | Uzedy, Austedo Xr |
| Biogen, INC. | $297.70 | 2022 | |
| Sanofi-Aventis U.S. LLC | $229.96 | 2022-2024 | |
| Dexcom, INC. | $214.38 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $211.12 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $182.88 | 2024 | Gemtesa |
| Sage Therapeutics, LLC | $178.90 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $172.66 | 2025 | |
| Vifor Pharma, INC. | $149.11 | 2022 | |
| Amgen INC. | $140.93 | 2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Donegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.